Soligenix (NASDAQ: SNGX) , a late-stage biopharmaceutical company focused on rare diseases, is featured in a new Benzinga video detailing clinical pr ...

Watch here: Soligenix $SNGX HyBryte™ Shows 75% Response Rate In Skin Cancer Trial, Backed By FDA Funding ...

Investing.com -- Shares of Soligenix (NASDAQ: SNGX) climbed 2.9% following the company’s announcement of promising results for its skin cancer treatment, HyBryteTM, in treating cutaneous T-cell ...